US20140249096A1

US20140249096A1 - Combination of compounds for treating or preventing skin diseases

Info

Publication number: US20140249096A1
Application number: US14/161,199
Authority: US
Inventors: André Jomard; Laurent Fredon; Olivier Roye
Original assignee: Galderma Research and Development SNC
Current assignee: Galderma Research and Development SNC
Priority date: 2009-02-16
Filing date: 2014-01-22
Publication date: 2014-09-04
Also published as: JP5538434B2; FR2942138A1; KR20110116059A; ES2545395T3; JP2012517989A; CN102395365B; EP2395998A1; RU2531087C2; CA2751543C; EP2395998B1; HK1166604A1; AU2010212634A1; MX2011008391A; BRPI1005931A2; BRPI1005931A8; KR101365011B1; AU2010212634B2; US8669233B2; US20120035123A1; RU2011138021A

Abstract

A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay, is described.

Description

The invention relates to a combination of compounds for treating skin diseases in humans, particularly rosacea and ocular rosacea.
Rosacea is a common chronic and progressive inflammatory dermatosis related to vascular relaxation. It mainly affects the central part of the face and is characterized by a reddening of the face or hot flushes, facial erythema, papules, pustules, telangiectasia and sometimes ocular lesions called ocular rosacea. In serious cases, particularly in men, the soft tissue of the nose can swell and produce a bulbous swelling called rhinophyma.
Rosacea generally occurs between the ages of 25 and 70, and it is much more common in people with a fair complexion. It affects more particularly women, although this disease is generally more severe in men. Rosacea is chronic and persists for years with periods of exacerbation and remission.
The pathogenesis of rosacea is poorly understood. Many factors may be involved without necessarily inducing this disease. They are, for example, psychological factors, gastrointestinal disorders, environmental factors (exposure to the sun, temperature, humidity), emotional factors (stress), food-related factors (alcohol, spices), hormonal factors, vascular factors, or even an infection with Helicobacter pilori.
Conventionally, rosacea is treated orally or topically with antibiotics such as tetracyclines, erythromycin or clindamycin, but also with vitamin A, salicylic acid, antifungal agents, steroids, metronidazole (an antibacterial agent) or with isotretinoin in severe forms or else with anti-infectives such as benzoyl peroxide or else with azelaic acid. The treatment of rosacea with ivermectin, which targets the Demodex folliculorum parasite present on the skin of patients, is also known (U.S. Pat. No. 5,952,372). The treatment of rosacea with alpha-1 or alpha-2 adrenergic receptor agonists is also known (US 2006/0171974A1, US 2005/0165079A1, US 2005/0020600A1).
These treatments have side effects that are unpleasant for the patient, such as irritation or intolerance phenomena. In addition, none of the existing treatments make it possible to effectively treat and/or prevent all the symptoms associated with rosacea.
Taking into account the aforementioned, there is therefore a need to produce a more effective treatment for rosacea, which does not have the side effects observed in the prior art There is in particular a need to produce a composition which confers a greater tolerance of the active ingredients, while at the same time reducing their side effects.
Surprisingly, the applicant has observed that a combination of a compound of the avermectin family or of the milbemycin family with a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family allows a more effective treatment of rosacea, with fewer side effects irrespective of the duration of application of this combination. In particular, such a combination makes it possible to substantially reduce the duration of treatment and to obtain a greater reduction in the symptoms of rosacea. This combination may also make it possible to eliminate the rebound effect normally observed at the end of treatment with alpha-1 or alpha-2 adrenergic receptor agonists.
A subject of the invention is a combination of a compound of the avermectin family or of the milbemycin family with a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family, for application thereof as a medicament for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea.
A subject of the invention is also the use of a combination of a compound of the avermectin family or of the milbemycin family with a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family for the production of a medicament intended for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea.
A subject of the present invention is also a pharmaceutical, in particular dermatological, composition comprising, in a physiologically acceptable medium, at least one compound of the avermectin family or of the milbemycin family and at least one compound of the alpha-1 or alpha-2 adrenergic receptor agonist family, intended for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea.

FIG. 1 is a graph of the average measurement of ear edema thickness in the evaluation of the anti-inflammatory activity of ivermectin and brimonidine after a single topical application in the arachidonic acid-induced mouse ear edema test.

FIG. 2 is a graph of the average measurement of ear edema thickness in the evaluation of the anti-inflammatory activity of ivermectin and brimonidine after a single topical application in the TPA-induced mouse ear edema test.

The term “dermatological composition” is intended to mean a pharmaceutical composition applied to the skin.
The term “physiologically acceptable medium” is intended to mean a medium that is compatible with the skin, the mucous membranes and/or the skin appendages.
The term “skin diseases” is intended to mean cutaneous and ocular disorders. By way of nonlimiting example, mention may be made of acne, hyperseborrhea, rosacea, ocular rosacea, psoriasis and atopic dermatitis.
The skin infection is more particularly rosacea or ocular rosacea.
A subject of the invention is also the use of such a composition for the production of a medicament intended for preventing and/or treating skin diseases and particularly rosacea and ocular rosacea.
A subject of the invention is also a product in the form of a kit compressing:
(a) a first composition comprising a compound of the avermectin family or of the milbemycin family, and
(b) a second composition different from the first one and comprising a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family,
as a combination product for application thereof as a medicament for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay,
A subject of the invention is also the use of a product in the form of a kit containing:
(a) a first composition comprising a compound of the avermectin family or of the milbemycin family, and
(b) a second composition different from the first one and comprising a compound of the alpha-1 or alpha-2 adrenergic receptor agonist
as a combination product for the production of a medicament intended for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay.
According to the invention, the compound of the avermectin family is advantageously chosen from ivermectin, invermectin, avermectin, abamectin, doramectin, eprinomectin and seiamectin, aversectin B, AB or C, emamectin B1a, emamectin B1b and their derivatives, or latidectin. The compound of the avermectin family is preferably ivermectin.
According to the invention, the compound of the milbemycin family is advantageously chosen from lepimectin, milbemectin, milbemycin oxime, moxidectin, 6′-ethyliepimectin, 6′-methyllepimectin and its derivatives or nemadectin α, β, γ or δ.
According to the invention, the compound of the alpha-1 adrenergic receptor agonist family is advantageously chosen from metaraminol bitartrate, midodrine, methoxamine, mephentermine, phenylephrine, oxymetazoline, tetrahydrozoline, naphazoline or xylometazoline, or their salts.
More particularly, the compound of the alpha-1 adrenergic receptor agonist family, as defined above, is in hydrochloride or bitartrate form.
According to the invention, the compound of the alpha-2 adrenergic receptor agonist family is advantageously chosen from apraclonidine, brimonidine, clonidine, mirtazapine, dexmedetomidine, guanbenz acetate, lidamidine, lofexidine, methyldopa, rilmenidine, talipexole, tiamenidine, tizanidine, tolonidine or their salts.
More particularly, the compound of the alpha-2 adrenergic receptor agonist family, as defined above, is in tartrate form.
More particularly, the compound of the alpha-2 adrenergic receptor agonist family may be brimonidine or its tartaric salt.
The combination according to the invention mare particularly contains a compound of the avermectin family and a compound of the alpha-2 adrenergic receptor agonist family.
Preferentially, the combination according to the invention contains brimonidine and ivermectin.
In the context of the present invention, a combination of a compound of the avermectin family or of the milbemycin family with a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family means that said combined compounds can be either present in the same composition, or present separately from one another in separate compositions, forming for example a product in the form of a kit. In other words, these compounds are intended to be administered to a patient in the context of the same treatment, i.e. over a common period of treatment, either at the same time, optionally being included in one and the same composition, or at different moments. Furthermore, they can be administered by identical or different administration methods and/or be included in identical or different compositions.
The combination of the abovementioned compounds present separately in separate compositions, and in particular in the case of a product in the form of a kit, makes it possible to limit the interactions of the compound(s) of the avermectin family, in particular ivermectin, or of the milbemycin family, with the compound(s) of the alpha-1 or alpha-2 adrenergic receptor agonist family. This also makes it possible to limit as much as possible the interactions of the compound(s) of the avermectin family, in particular ivermectin, or of the milbemycin family, with the numerous excipients normally contained in a single composition, and in particular the excipients contained in the composition comprising the compounds of the alpha-1 or alpha-2 adrenergic receptor agonist family. The compositions according to the invention, applied simultaneously or successively, are thus very well tolerated, precise in terms of amount of active compounds delivered, and practical to use. They also offer the patients comfort and hydration,
In the case of a combination of the abovementioned compounds present separately in separate compositions, and in particular in the case of a product in the form of a kit, a compound of the avermectin family or of the milbemycin family can first be applied to the skin of a patient, and then a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family can be applied, or vice versa.
In the compositions according to the invention, the compound of the avermectin family or of the milbemycin family is present at a concentration of between 0.001 and 10% by weight, relative to the total weight of the composition comprising it, preferably between 0.01 and 5% by weight, and in particular 0.75%, 1%, 1.5% or 2%. When a composition comprises several of these compounds, their total concentration is included in the abovernentioned amounts.
In the compositions according to the invention, the compound of the alpha-1 or alpha-2 adrenergic receptor agonist family is present at a concentration of between 0.01 and 20% by weight, relative to the total weight of the composition, preferably between 0.02 and 10%, particularly preferably between 0.05 and 5% by weight, relative to the total weight of the composition. When a composition comprises several of these compounds, their total concentration is included in the abovementioned amounts.
Particularly preferably, the combination comprises a compound of the avermectin family or of the milbemycin family present at a concentration of between 0.01 and 5% by weight, relative to the total weight of the composition comprising K. and a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family present at a concentration of between 0.01 and 5% by weight, relative to the total weight of the composition.
Said composition according to the invention contains more particularly a compound of the avermectin family and a compound of the alpha-2 adrenergic receptor agonist family.
Preferentially, the composition according to the invention comprises brimonidine and ivermectin.
The combination according to the invention and the compositions comprising the compounds of this combination are in particular intended for topical application to the skin and/or for ocular application to the eyes.
The compositions of the invention also comprise a pharmaceutically or cosmetically acceptable vehicle, i.e. a vehicle suitable for use in contact with human cells, without toxicity, irritation, undue allergic response and the like, and proportioned at a reasonable advantage/risk ratio.
The compositions of the invention may also comprise at least one other therapeutic agent capable of increasing the efficacy of the treatment.
The compositions of the invention may also comprise any additive normally used in the pharmaceutical or dermatological field, which is compatible with the compound of the avermectin family or of the milbemycin family and/or the compound of the alpha-1 or alpha-2 adrenergic receptor agonist family that is/are present.
Mention may in particular be made of sequestering agents, antioxidants, sunscreens, preservatives, for example DL-alpha-tocopherol, fillers, electrolytes, humectants, colorants, of customary inorganic or organic bases or acids, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, artificial tanning compounds such as DHA, agents for soothing and protecting the skin, such as allantoin, propenetrating agents, gelling agents, or a mixture thereof. Of course, those skilled in the art will take care to select this or these optional additional compound(s), and/or the amount thereof, in such a way that the advantageous properties of the composition according to the invention are not, or not substantially, impaired.
These additives may be present in the composition in a proportion of from 0 to 20% by weight, relative to the total weight of the composition,
The administration may be carried out topically, enterally or orally, parenterally or ocularly.
Among these routes of administration, the topical route and the ocular route are particularly preferred.
The compositions of the present invention may be in any of the galenical forms normally used for topical administration, in particular in the form of solutions, lotions, gels, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O/W) or vice versa (W/O), or suspensions or emulsions of soft, semi-liquid or solid consistency, of the cream or ointment type, or else microemulsions, microcapsules, microparticles or vesicular dispersions of ionic and/or nonionic type.
Advantageously, the composition comprises an ointment, a cream, a lotion or a gel.
By way of illustration and without being in any way limiting in nature, various formulations of compositions according to the invention and also the results of a study of the anti-inflammatory activity of the combination of a compound of the avermectin family or of the milbemycin family with a compound of the alpha-1 or alpha-2 adrenergic receptor agonist family will now be given.

EXAMPLE


		% by weight relative to
		the total weight of the
	Ingredients	composition

	Ivermectin	1.00
	Brimonidine tartrate	0.20
	EDTA	0.1
	Polysorbate 80	8.0
	Propylene glycol	20.00
	Benzyl alcohol	3
	Water	qs 100

EXAMPLE 2


		% by weight relative to
		the total weight of the
	Ingredients	composition

	Emamectin	0.5
	Brimonidine tartrate	0.3
	Codex petroleum jelly	56.00
	Liquid petroleum jelly	43.00

EXAMPLE 3


		% by weight relative to
		the total weight of the
	Ingredients	composition

	Ivermectin	1.40
	Oxymetazoline hydrochloride	0.20
	Glycerol	4.0
	Steareth-2	1.0
	Steareth-21	2.0
	Aluminum magnesium	1.0
	silicate/titanium dioxide/silica
	Methyl para-hydroxybenzoate	0.2
	Propyl para-hydroxybenzoate	0.1
	Disodium EDTA	0.05
	Citric acid monohydrate	0.05
	Isopropyl palmitate	4.0
	Glyceryl/PEG 100 stearate	2.0
	Self-emulsifiable wax	1.0
	Palmitostearic acid	2.00
	Dimethicone 200-350 cS	0.5
	Propylene glycol	4.0
	Glyceryl triacetate	1.00
	Phenoxyethanol	0.5
	10% sodium hydroxide	qs pH
	Water	qs 100

EXAMPLE 4


		% by weight relative to the total
	Ingredients	weight of the composition

	Ivermectin	0.03
	Brimonidine	0.15
	Polysorbate 80	2.00
	Benzalkonium chloride	0.05
	EDTA	0.05
	Water	qs 100
	Buffer system	pH 6.3

EXAMPLE 5

Evaluation of the Anti-Inflammatory Activity of Ivermectin and of Brimonidine after a Single Topical Application in the Arachidonic Acid-Induced Mouse Ear Edema Test on Balb/c Mice

Arachidonic acid is dissolved in a mixture of THF/methanol at 4%.
Treatment:
Ivermectin is dissolved in the solution of arachidonic acid (AA) and tested at the concentration of 1%.
20 μl of the solution are applied to the internal surface of the right ear.
The thickness of the ear is measured at T+1 h, T+2 h and T+4 h.
Results:
FIG. 1 represents the average measurement of the thickness of the ear edema, i.e. the average measurement of the thickness of the ear after treatment, from which is subtracted the average measurement of the thickness of the ear obtained with the control (nontreated) group, this being after treatment with 4% arachidonic acid (
), 1% ivermectin (
), 0.2% brimonidine (
), and the combination of ivermectin and brimonidine (
).
Indomethacin (positive control) at 5% inhibits the ear edema caused by arachidonic acid by 95% (*“),
Ivermectin alone (1%) reduces the ear edema by 56% (**).
The combination of ivermectin (1%) with brimonidine (0.2%) inhibits the ear edema caused by arachidonic add by 84% (***), it therefore shows a strong anti-inflammatory effect in the arachidonic acid-induced mouse ear edema model

EXAMPLE 6

Evaluation of the Anti-Inflammatory Activity of Ivermectin and of Brimonidine after a Single Topical Application in the TPA Induced Mouse Ear Edema Test on Balb/c Mice

Treatment:
The edema is induced by means of a single application of 20 μl of TPA (phorbol 12-myristate 13-acetate) dissolved in ethanol at 0.01%.
The test compounds are diluted in the TPA solution.
A positive control, β-methasone valerate (BMV) at 0.01% is also tested; it inhibits the mouse ear edema by 89%.
Ivermectin is applied at a concentration of 0.1%, 0.3% and 1%. Brimonidine added at the concentration of 0.2%,
The thickness of the mouse ear is measured at T+6 h.
Resuits:
The results are presented in FIG. 2.
FIG. 2 represents the average measurement of the ear edema thickness as a function of the dose of test compound as %, i.e. the average measurement of the ear thickness after treatment, from which is subtracted the average measurement of the thickness of the ear obtained with the control (nontreated) group,
this being after treatment with TPA at 0.01% (
),
ivermectin at respectively 0.1, 0.3 and 1% (
),
brimonidine at 0.2% (
),
the combination of ivermectin and brimonidine (
).
After a single topical application of ivermectin at 0.3% and 1% diluted in the TPA solution, a reduction in the ear edema of respectively 57% (**) and 90% (***) is observed.
The application of brimonidine alone at 0.2% reduces the mouse ear edema by 50%.
The combination of ivermectin (at 0.1, 0.3 and 1%) and brirnonidine (0.2%) has a dose-dependent anti-inflammatory effect, and reduces the TPA-inciuced ear edema by, respectively, 91% (***) (at 0.1%), 94% (“'”) (at 0.3%) and 100% (***) (at 1%).

Claims

1-32. (canceled)

33. A method for treating rosacea, the method comprising topically administering to a subject in need of such treatment, a first pharmaceutical composition comprising, in a physiologically acceptable medium, ivermectin in an amount of 0.01% to 5% by weight of the composition, and a second pharmaceutical composition comprising, in a physiologically acceptable medium, brimonidine or a salt thereof in an amount of from 0.01% to 5% by weight of the composition, the first composition being administered first and the second composition being administered thereafter, or the second composition being administered first and the first composition being administered thereafter, or both compositions being administered simultaneously.

34. The method as claimed in claim 33, wherein the second pharmaceutical composition comprises, in a physiologically acceptable medium, brimonidine or brimonidine tartrate in an amount of from 0.01% to 5% by weight of the composition.

35. The method as claimed in claim 34, wherein the ivermectin is present in an amount of 0.1%, 0.3% or 1% by weight of the composition.

36. The method as claimed in claim 33, wherein the first pharmaceutical composition comprises, in a physiologically acceptable medium, ivermectin in an amount of 0.1%, 0.3% or 1% by weight of the composition, and the second pharmaceutical composition comprises, in a physiologically acceptable medium, brimonidine in an amount of 0.2% by weight of the composition.